Cardiology Topic Homepage

Cardiology Overview

Cardiology

In 2008, cardiovascular diseases (CVD) were responsible for 17.3 million deaths worldwide - almost a third of global deaths. However death rates vary worldwide with the low and middle-income countries representing 80% of these deaths.1

In Europe Coronary Heart Disease and Stroke have the highest death rates killing 1.92 million and 1.24 million respectively each year.2

The death rate from CVD has...

... decreased in Northern and Western Europe for example the death rate in men under 65 years decreased by 37% in Finland and by 42% in UK between 1994 and 2004. The trend is the same for women under 65 years with 35% and 49% of decrease respectively in Finland and UK within the same time.2

On the other hand, the death rate has increased in Central and Eastern Europe for example the death rate in men under 65 years increased by 57% and 19% in Albania and Ukraine respectively between 1994 and 2004. The trend is the same for women under 65 years in these countries with a 46% and 19% increase respectively within the period.2

Diseases of the cardiovascular system include hypertension,acute coronary syndrome or ACS, heart failure , stroke, cardiac arrhythmias, cardiac conduction defect, pericarditis, congenital heart disease, cardiac valvulopathy and venous thromboembolism.3

Although hypertension is a CVD, it's also a risk factor for other CVD. The risk of developing subsequent CVD is higher with more severe hypertension.4

Cardiac arrhythmias and cardiac conduction disorders are mainly represented by atrial fibrillation and bradycardia.5

Patients with atrial fibrillation are five times more likely to suffer a stroke, while those with either atrial fibrillation or myocardial infarction have an increased risk of heart failure.5

Acute Coronary Syndrome (ACS) and stroke are usually the end result of atherosclerosis -which is the most common cause of deaths in industrialised countries. Atherosclerosis is the formation of a plaque in the blood vessels. Its main components are LDL-cholesterol and its mechanism of formation is accurately described in both the Cholesterol and Heart Failure Knowledge Centres.

The main CVD modifiable risk factors are tobacco, excessive alcohol consumption, diet (salt and fat), physical inactivity, obesity, stress and diabetes. Usually, people combine several of these risk factors creating a synergic effect.3 By altering these lifestyle choices, 80% of cardiovascular diseases could be prevented.1

Some other risk factors are non modifiable such as, increased age, male gender and positive family history.3

There are two types of prevention: primary (to prevent atherosclerosis) and secondary (to prevent disease exacerbation).

Diagnostic techniques include blood pressure measurement, ECG, chest X-Ray, Echocardiography, cardiac catheterization, MRI and blood tests (K+, Cholesterol, Haemoglobin, natriuretic peptides).3

The treatment of CVD, can be divided in two categories. For ACS pharmacological management (e.g. statins) and non pharmacological management are available. For hypertension, the approach is similar, treated with both lifestyle and pharmacological intervention. The main goals of many CVD treatments are to lower LDL-C and blood pressure and prevent thrombus formation (anticoagulant agents).

References
  1. WHO, Fact Sheet N317 september 2011, available at: http://www.who.int/mediacentre/factsheets/fs317/en/index.html, accessed the 20th of September 2012
  2. The European Heart Network, European cardiovascular Statistics 2008 Edition available at: http://www.herzstiftung.ch/uploads/media/European_cardiovascular_disease_statistics_2008.pdf, accessed the 20th of September 2012
  3. Beers M.H. et al. The Merck manual of medical information. Merck research laboratories. Second home edition. 2003, 113-239
  4. NICE clinical Guideline, Hypertension Clinical Management of Primary Hypertension in Adults, August 2011, available at: http://www.nice.org.uk/nicemedia/live/13561/56008/56008.pdf, accessed the 20th of September 2012
  5. European Society of Cardiology, Guidelines for the Management of Atrial Fibrillation, 2010, available at: http://www.escardio.org/guidelines-surveys/esc-guidelines/GuidelinesDocuments/guidelines-afib-FT.pdf, accessed the 20th of September 2012

Heart Failure

Heart Failure is a progressive chronic disorder that results in the inability of the heart to pump blood efficiently to the body’s tissues.

Chronic heart failure is an increasing public health problem; the growing prevalence in industrialised countries means that 1-2% of the adult population of these countries are now thought to have chronic heart failure.1-3 Estimates suggest that the prevalence in Europe, USA and Japan could increase by approximately 16.5% over the next ten years.4

The prevalence of post-myocardial infarction heart failure is less well known as it is difficult to distinguish between pre-existing and incident heart failure. However current estimates suggest that approximately 1 in 5 patients hospitalised with an acute coronary syndrome either present with heart failure or develop heart failure during their hospital stay.5

Many of the signs and symptoms of heart failure are non-specific and vary in severity depending on the disease class. The most common of these are breathlessness, fatigue, exercise intolerance, and fluid retention as evidenced by ankle swelling, peripheral oedema, and an elevated jugular venous pressure.6

Due to the non-specific nature of symptoms, the diagnosis of heart failure can be difficult. Tests can include echocardiogram, ECG, chest X-ray, laboratory tests. Following a positive diagnosis heart failure is classified into functional classes that relate to disease severity.

Management of heart failure involves lifestyle modifications, pharmacological treatment and occasionally surgery. In patients with chronic heart failure, optimal therapy involves treatment with diuretics, ACE inhibitors, certain β-blockers and a mineralocorticoid receptor antagonist.

The Heart Failure Knowledge Centre brings together current information related to chronic heart failure and post-myocardial infarction, including:

  • Epidemiology
  • Symptoms and Diagnosis
  • Classification
  • Treatment Options
Enter the Heart Failure Knowledge Centre

References

  1. Zannad F, et al. Incidence, clinical and etiologic features, and outcomes of advanced chronic heart failure: the EPICAL Study. Journal of the American College of Cardiology 1999; 33(3):734-742.
  2. Cowie MR, et al. The epidemiology of heart failure. European Heart Journal 1997;18(2):208-225.
  3. Mosterd A, Hoes A. Clinical epidemiology of heart failure. Heart 2007; 93:1137-1146.
  4. Decision Resources. Chronic Heart Failure. Cardium Study No.4 A Pharmacor Service. 2008.
  5. Steg PG, Dabbous OH, et al. Determinants and prognostic impact of heart failure complicating acutecoronary syndromes. Observations from the Global Registry of Acute Coronary Events (GRACE). Circulation2004;109:494-9.
  6. NICE Clinical Guideline No 108. Chronic Heart Failure. National clinical guideline for diagnosis and management in primary and secondary care. 2010.

Clinical Case Studies

MRSA Endocarditis

Infection: Cardiovascular Infections

Christopher D. Pfeiffer, Clinical Fellow, Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA
Vance Fowler, Associate Professor and Infectious Diseases, Specialist, Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA

Case History
A 64-year-old female presented with three weeks of progressive dyspnoea, nausea and vomiting.

Vascular Graft Infection

Infection: Cardiovascular Infections

Stephanie J. Dancer BSc, MB BS, MSc, MD, FRCPath, DTM&H, Consultant Microbiologist, NHS Lanarkshire, Scotland

Case History
A 72-year-old man was referred by his general practitioner complaining of intermittent pain in the legs on exercise.

Drug News

RELY-ABLE trial shows long-term safety profile of Pradaxa (Boehringer) in patients with Atrial Fibrillation

16-06-2013

Results from the RELY-ABLE trial, a long-term extension of the pivotal RE-LY study of Pradaxa (dabigatran etexilate), from Boehringer, in patients with non-valvular Atrial Fibrillation (NVAF),...

FDA approves Ellipse and SJM Assura ICDs and CRT-Ds (St Jude Medical) for Heart Failure

15-06-2013

The FDA has approved the next-generation Ellipse and SJM Assura portfolio of implantable Cardioverter Defibrillators (ICDs) and Cardiac Resynchronization Therapy Defibrillators (CRT-Ds), from St...

Phase III data on Gencaro (ARCA biopharma) shows drug effective on genetic subset of Atrial Fibrillation patients

08-06-2013

New results of a Phase III trial of Gencaro (bucindolol hydrochloride), from ARCA biopharma, in reducing the incidence of new onset Atrial Fibrillation in patients with advanced heart failure with...

Cardiology Drug Data - A-Z

Possible searches include drugs or medicines (by brand, generic ingredient or drug class), diseases, conditions and more.

Drug Lang:

Recent Drug Updates

Omacor

13-06-2013

Post Myocardial Infarction Adjuvant treatment in secondary prevention after myocardial infarction, in addition to other standard therapy (e.g. statins, anti-platelet medicinal products, ...

Aprovel Film-Coated Tablets (sanofi-aventis Bristol-Myers Squibb SNC)

14-05-2013

Aprovel is indicated in adults for the treatment of essential hypertension. It is also indicated for the treatment of renal disease in adult patients with hypertension and type 2 diabetes mellitus...

Ranexa prolonged-release tablets

08-05-2013

Ranexa is indicated in adults as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line antianginal...

Clinical Guidelines

Ivabradine for treating chronic heart failure

Nov 2012

Ivabradine (Procoralan, Servier Laboratories) is a heart-rate-lowering agent that selectively and..

... specifically inhibits the cardiac pacemaker If current, which controls the spontaneous diastolic depolarisation in the sinus node that regulates the heart rate.

2012 focused update of the ESC Guidelines for the management of atrial fibrillation

Aug 2012

The current estimate of the prevalence of atrial fibrillation (AF) in the developed world is..

... approximately 1.5–2% of the general population, with the average age of patients with this condition steadily rising, such that it now averages between 75 and 85 years. The arrhythmia is associated with a five-fold risk of stroke and a three-fold incidence of congestive heart failure, and higher mortality. Hospitalization of patients with AF is also very common. This arrhythmia is a major cardiovascular challenge in modern society and its medical, social and economic aspects are all set to worsen over the coming decades. Fortunately a number of valuable treatments have been devised in recent years that may offer some solution to this problem.

Clinical Trials

Non-invasive Diagnostics of Pulmonary Hypertension With Dual Energy Computed Tomography

09-04-2013

The aim of the study is to determine relevant hemodynamic parameters for the diagnostics of pulmonary arterial hypertension (PAH) by dynamic contrast enhanced dual-energy CT (DE-CT). In this prospective study the investigators validate DE-CT results of patients against hemodynamic parameters from right heart..

... catheterisation and control the results by other clinical investigations. The investigators expect that using this non-invasive method, parameters relevant for the diagnosis of the patients with PAH, like pulmonary blood volume, blood flow and perfusion heterogeneity, can be determined.

Comparison of Low and Intermediate Dose Low-molecular-weight Heparin to Prevent Recurrent Venous Thromboembolism in Pregnancy

05-04-2013

This is a randomized-controlled open-label trial comparing two different doses of low-molecular-weight heparin (LMWH) in pregnant patients with a history of previous venous thromboembolism (VTE). Both doses are recommended doses in the 2012 guidelines of the American College of Chest Physicians (ACCP), but it is not..

... known which dose is more efficacious in preventing recurrent venous thromboembolism in pregnancy.

Medical Videos

3D Medical Animation - Congestive Heart Failure
3D Medical Animation - Congestive Heart Failure
A Discussion of Interventional Cardiology and the Procedures Involved
A Discussion of Interventional Cardiology and the Procedures Involved
A Guide to the Coronary Angioplasty Procedure
A Guide to the Coronary Angioplasty Procedure
Animation: New therapy prevents heart failure
Animation: New therapy prevents heart failure
Advances in Dual Antiplatelet Therapy for Acute Coronary Syndrome (ACS)
Advances in Dual Antiplatelet Therapy for Acute Coronary Syndrome (ACS)
The Lead: Time to Abandon LDL Treatment Targets?
The Lead: Time to Abandon LDL Treatment Targets?
Discussion of a Paper on the use of GPI's During Coronary Angioplasty Surgery
Discussion of a Paper on the use of GPI's During Coronary Angioplasty Surgery

Medical Journal Abstracts

Cardiopulmonary resuscitation in the pregnant patient: a manikin-based evaluation of methods for producing lateral tilt

Anaesthesia
May 2013

The importance of minimising aortocaval compression during cardiopulmonary resuscitation in late pregnancy is widely accepted. Current European guidelines suggest employing manual displacement of the uterus with left lateral tilt to achieve this. Several methods for producing lateral tilt have been described; however,..

Changes in cardiac index and blood pressure on positioning children prone for scoliosis surgery

Anaesthesia
May 2013

In this prospective observational study we investigated the changes in cardiac index and mean arterial pressure in children when positioned prone for scoliosis correction surgery. Thirty children (ASA 1–2, aged 13–18 years) undergoing primary, idiopathic scoliosis repair were recruited. The cardiac index and mean..

Social Media

ECG Quiz

on doc2doc

ECG Quiz AF with Complete Heart Block.Dr.Chid

Frailty. Is it an important clinical syndrome?

on doc2doc

... or the consequences of treating certain diseases like malignancies, cardiovascular disorders or stroke, rather than a separate syndrome. Management of ...

Frailty. Is it an important clinical syndrome?

on doc2doc

... treatments, one should consider doses in patients with renal failure, heart failure, liver dysfunction, depressed immune system, undernourished ...

Back to top